Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
NCT07728669 · Recruiting
Last updated 2026-08-27This clinical trial is testing a digital dietary intervention in adults with type 2 diabetes, obesity, or metabolic syndrome who are receiving GLP-1 receptor agonist therapy to see how it affects their blood sugar levels over 12 weeks.
What this study is testing ClinicalTrials.gov NCT07728669 ↗
Description as written by the study sponsor.
The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or overweight with related health conditions. Participants are already receiving or have been prescribed glucagon-like peptide-1 (GLP-1) receptor agonist therapy by their treating physicians outside the study. The main question is: Does the NutriSteppe digital dietary intervention improve glycated hemoglobin (HbA1c), a measure of average blood glucose, after 12 weeks compared with routine medical care alone? The study will also assess changes in fasting blood glucose, body weight, body mass index, waist circumference, cholesterol, triglycerides, blood pressure, diet quality, quality of life, dietary adherence, and safety. Researchers will randomly assign participants to one of two groups. The control group will continue routine medical care and receive general lifestyle advice. The intervention group will continue routine medical care and use the NutriSteppe application for 12 weeks to receive personalized dietary support. Participants in both groups will: * Attend study visits and complete the examinations, laboratory tests, and questionnaires specified in the study protocol. * Photograph everything they eat and drink. * Have their food photographs automatically analyzed using Tagam-AI, a system developed for this study. * Be able to view the results of the food photograph analysis. The photography and automated analysis procedures will be the same in both groups. Only participants in the intervention group will receive personalized dietary recommendations generated from these data through the NutriSteppe application.
Treatments tested
- NutriSteppe Digital Dietary Intervention Behavioral
The NutriSteppe mobile application provides personalized meal planning, a food diary, nutritional analysis, dietary goals, educational modules, culturally adapted recipes, progress monitoring, reminders, and dietary recommendations intended to support metabolic health and food tolerance during GLP-1 receptor agonist therapy. Participants use the application for 12 weeks, complete the food diary at least 5 days per week, record body weight weekly, review dietary suggestions, and complete weekly educational modules.
| Main thing measured | Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 |
|---|---|
| Sponsor | Kazakh Academy of Nutrition |
| Conditions studied | Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder), Overweight, Metabolic Syndrome |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07728669 ↗